| Nov 12 |
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
|
| Nov 4 |
Enveric Biosciences Announces Broad Range of Patent Issuances
|
| Oct 15 |
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
|
| Sep 26 |
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
|
| Sep 25 |
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
|
| Sep 4 |
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 13 |
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
|
| Aug 13 |
Enveric Biosciences GAAP EPS of -$0.23
|
| Aug 12 |
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
|
| Jul 30 |
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
|
